loading
前日終値:
$7.70
開ける:
$7.95
24時間の取引高:
63,262
Relative Volume:
1.29
時価総額:
$17.82M
収益:
-
当期純損益:
$-4.85M
株価収益率:
-24.58
EPS:
-0.31
ネットキャッシュフロー:
$-3.95M
1週間 パフォーマンス:
+3.39%
1か月 パフォーマンス:
+2.83%
6か月 パフォーマンス:
-33.68%
1年 パフォーマンス:
-60.70%
1日の値動き範囲:
Value
$7.54
$8.1699
1週間の範囲:
Value
$6.85
$8.21
52週間の値動き範囲:
Value
$6.42
$22.90

Cadrenal Therapeutics Inc Stock (CVKD) Company Profile

Name
名前
Cadrenal Therapeutics Inc
Name
セクター
Healthcare (1113)
Name
電話
904-300-0701
Name
住所
822 A1A NORTH, PONTE VEDRA
Name
職員
4
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
CVKD's Discussions on Twitter

CVKD を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
CVKD
Cadrenal Therapeutics Inc
7.62 18.00M 0 -4.85M -3.95M -0.31
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.17 120.98B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
771.25 80.15B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
864.42 51.56B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
354.75 47.74B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
336.16 37.38B 4.98B 69.59M 525.67M 0.5197

Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-12-18 開始されました Noble Capital Markets Outperform

Cadrenal Therapeutics Inc (CVKD) 最新ニュース

pulisher
Jan 23, 2026

Aug Momentum: Is Cadrenal Therapeutics Inc stock overvalued or fairly pricedMarket Volume Summary & Advanced Swing Trade Entry Plans - baoquankhu1.vn

Jan 23, 2026
pulisher
Jan 20, 2026

Why is Cadrenal Therapeutics stock drawing retail attention today? - MSN

Jan 20, 2026
pulisher
Jan 19, 2026

Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today? - Stocktwits

Jan 19, 2026
pulisher
Jan 19, 2026

Cadrenal Advances Anticoagulation Pipeline, VLX-1005 Completes Phase 2 Trial - Intellectia AI

Jan 19, 2026
pulisher
Jan 17, 2026

(CVKD) Risk Channels and Responsive Allocation - Stock Traders Daily

Jan 17, 2026
pulisher
Jan 15, 2026

CVKD: VLX-1005 and Tecarfarin lead a strategy to address unmet needs in rare anticoagulation markets - TradingView — Track All Markets

Jan 15, 2026
pulisher
Jan 15, 2026

CVKD: VLX-1005 and tecarfarin drive innovation in underserved anticoagulation markets, with key milestones ahead - TradingView — Track All Markets

Jan 15, 2026
pulisher
Jan 15, 2026

Trend Report: Can GMGI stock double in the next yearJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - baoquankhu1.vn

Jan 15, 2026
pulisher
Jan 13, 2026

Income Plays: Is Cadrenal Therapeutics Incs ROIC above industry averageEarnings Miss & Fast Moving Stock Watchlists - baoquankhu1.vn

Jan 13, 2026
pulisher
Jan 13, 2026

Cadrenal highlights potential of 12-LOX inhibitor for blood disorder By Investing.com - Investing.com Nigeria

Jan 13, 2026
pulisher
Jan 12, 2026

Cadrenal highlights potential of 12-LOX inhibitor for blood disorder - Investing.com

Jan 12, 2026
pulisher
Jan 12, 2026

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX In - GlobeNewswire

Jan 12, 2026
pulisher
Jan 12, 2026

New drug aims to cut dangerous blood clots from a rare reaction to heparin - Stock Titan

Jan 12, 2026
pulisher
Jan 10, 2026

Cadrenal Therapeutics, Inc. - MSN

Jan 10, 2026
pulisher
Jan 09, 2026

Will Cadrenal Therapeutics Inc. stock keep outperforming rivals2025 Key Highlights & Community Verified Watchlist Alerts - Улправда

Jan 09, 2026
pulisher
Jan 09, 2026

Will Cadrenal Therapeutics Inc. stock benefit from commodity pricesWeekly Trend Summary & Real-Time Volume Trigger Notifications - Улправда

Jan 09, 2026
pulisher
Jan 08, 2026

Can Cadrenal Therapeutics Inc. stock deliver consistent earnings growthMarket Performance Summary & Weekly Consistent Profit Watchlists - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

What sentiment indicators say about Cadrenal Therapeutics Inc. stockMarket Growth Report & Weekly Market Pulse Updates - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Risk Analysis: Why Cadrenal Therapeutics Inc. stock remains undervaluedBreakout Watch & Daily Profit Maximizing Tips - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

How Cadrenal Therapeutics Inc. stock trades during market volatilityJuly 2025 Institutional & Stepwise Trade Execution Plans - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Is Cadrenal Therapeutics Inc. stock a contrarian buyTrade Performance Summary & Step-by-Step Swing Trade Plans - Улправда

Jan 08, 2026
pulisher
Jan 07, 2026

Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN

Jan 07, 2026
pulisher
Jan 06, 2026

(CVKD) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Jan 06, 2026
pulisher
Jan 05, 2026

Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex

Jan 05, 2026
pulisher
Jan 02, 2026

Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock - Defense World

Jan 02, 2026
pulisher
Dec 30, 2025

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - The Globe and Mail

Dec 30, 2025
pulisher
Dec 30, 2025

How a small biotech is building an emergency anticoagulation plan - Stock Titan

Dec 30, 2025
pulisher
Dec 29, 2025

Cadrenal Therapeutics announces new securities purchase agreement - MSN

Dec 29, 2025
pulisher
Dec 29, 2025

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - ACCESS Newswire

Dec 29, 2025
pulisher
Dec 29, 2025

Inside the drug startup rebuilding blood thinners for medicine’s toughest cases - Stock Titan

Dec 29, 2025
pulisher
Dec 26, 2025

(CVKD) Volatility Zones as Tactical Triggers - Stock Traders Daily

Dec 26, 2025
pulisher
Dec 24, 2025

Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity - The Globe and Mail

Dec 24, 2025
pulisher
Dec 23, 2025

Cadrenal Therapeutics Appoints Dr. Golden to Board - MSN

Dec 23, 2025
pulisher
Dec 22, 2025

Cadrenal Therapeutics (NASDAQ:CVKD) & Biodexa Pharmaceuticals (NASDAQ:BDRX) Financial Analysis - Defense World

Dec 22, 2025
pulisher
Dec 20, 2025

Downgrade Watch: Will Cadrenal Therapeutics Inc stock benefit from commodity pricesEarnings Beat & Detailed Earnings Play Alerts - moha.gov.vn

Dec 20, 2025
pulisher
Dec 20, 2025

Is Cadrenal Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - ulpravda.ru

Dec 20, 2025
pulisher
Dec 20, 2025

How Cadrenal Therapeutics Inc. stock performs in stagflation2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Is Cadrenal Therapeutics Inc. stock recession proofWeekly Profit Recap & Capital Efficient Trading Techniques - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Is Cadrenal Therapeutics Inc. stock positioned for digital transformationInsider Buying & Community Verified Trade Signals - Улправда

Dec 20, 2025
pulisher
Dec 19, 2025

Can Cadrenal Therapeutics Inc. stock resist market sell offsJuly 2025 Movers & Technical Buy Zone Confirmations - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

Can Cadrenal Therapeutics Inc. stock deliver surprise earnings beatTrade Analysis Summary & Daily Entry Point Trade Alerts - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

Aug PreEarnings: Is Cadrenal Therapeutics Inc. stock a contrarian buy2025 Market Sentiment & Weekly High Momentum Picks - DonanımHaber

Dec 19, 2025
pulisher
Dec 18, 2025

Ideas Watch: Is Cadrenal Therapeutics Inc. stock positioned for digital transformationInsider Selling & Weekly Setup with ROI Potential - Улправда

Dec 18, 2025
pulisher
Dec 18, 2025

Is Cadrenal Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Opening Moves & Free Real-Time Market Sentiment Alerts - Улправда

Dec 18, 2025
pulisher
Dec 18, 2025

How Cadrenal Therapeutics Inc. stock responds to policy changes2025 Bull vs Bear & Expert Curated Trade Setups - Улправда

Dec 18, 2025
pulisher
Dec 18, 2025

Will Cadrenal Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Volume & Technical Pattern Based Signals - Улправда

Dec 18, 2025
pulisher
Dec 17, 2025

Cadrenal Therapeutics to conduct partnering and investor meetings - marketscreener.com

Dec 17, 2025
pulisher
Dec 17, 2025

Cadrenal Therapeutics To Conduct Partnering And Investor Meetings - TradingView — Track All Markets

Dec 17, 2025
pulisher
Dec 17, 2025

Cadrenal Therapeutics, Inc. Management to Hold Investor and Partner Meetings at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative

Dec 17, 2025
pulisher
Dec 17, 2025

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026 - Sahm

Dec 17, 2025

Cadrenal Therapeutics Inc (CVKD) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$99.82
price up icon 2.09%
$103.47
price up icon 0.87%
$34.40
price up icon 2.78%
$119.34
price up icon 1.14%
$162.64
price up icon 1.83%
biotechnology ONC
$336.16
price down icon 0.48%
大文字化:     |  ボリューム (24 時間):